Page last updated: 2024-10-30

lorglumide and Precancerous Conditions

lorglumide has been researched along with Precancerous Conditions in 2 studies

lorglumide: RN given refers to (+-)-isomer
lorglumide : A racemate comprising equal amounts of (R)- and (S)-lorglumide.
N(2)-(3,4-dichlorobenzoyl)-N,N-dipentyl-alpha-glutamine : A dicarboxylic acid monoamide obtained by formal condensation of the alpha-carboxy group of N-(3,4-dichlorobenzoyl)glutamic acid with the amino group of dipentylamine.

Precancerous Conditions: Pathological conditions that tend eventually to become malignant.

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19901 (50.00)18.7374
1990's1 (50.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Watanapa, P1
Flaks, B1
Oztas, H1
Deprez, PH1
Calam, J1
Williamson, RC1
Douglas, BR1
Woutersen, RA1
Jansen, JB1
de Jong, AJ1
Rovati, LC1
Lamers, CB1

Other Studies

2 other studies available for lorglumide and Precancerous Conditions

ArticleYear
Inhibitory effect of a cholecystokinin antagonist on pancreatic carcinogenesis after pancreatobiliary diversion.
    British journal of cancer, 1993, Volume: 67, Issue:4

    Topics: Animals; Azaserine; Biliopancreatic Diversion; Body Weight; Cholecystokinin; Cocarcinogenesis; Male;

1993
Modulation by CR-1409 (lorglumide), a cholecystokinin receptor antagonist, of trypsin inhibitor-enhanced growth of azaserine-induced putative preneoplastic lesions in rat pancreas.
    Cancer research, 1989, May-01, Volume: 49, Issue:9

    Topics: Animals; Azaserine; Cholecystokinin; Esters; Gabexate; Glutamine; Guanidines; Male; Pancreatic Neopl

1989